Sonoma Pharmaceuticals (STU:O8Z) Other Net Income (Loss) : €-0.00 Mil (TTM As of Dec. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Sonoma Pharmaceuticals Other Net Income (Loss)?

Sonoma Pharmaceuticals's Other Net Income (Loss) for the three months ended in Dec. 2024 was €0.00 Mil. Its Other Net Income (Loss) for the trailing twelve months (TTM) ended in Dec. 2024 was €-0.00 Mil.

Sonoma Pharmaceuticals's quarterly Other Net Income (Loss) declined from Jun. 2024 (€0.00 Mil) to Sep. 2024 (€-0.00 Mil) but then increased from Sep. 2024 (€-0.00 Mil) to Dec. 2024 (€0.00 Mil).

Sonoma Pharmaceuticals's annual Other Net Income (Loss) declined from Mar. 2022 (€0.00 Mil) to Mar. 2023 (€0.00 Mil) but then increased from Mar. 2023 (€0.00 Mil) to Mar. 2024 (€0.00 Mil).

Sonoma Pharmaceuticals Other Net Income (Loss) Historical Data

The historical data trend for Sonoma Pharmaceuticals's Other Net Income (Loss) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sonoma Pharmaceuticals Other Net Income (Loss) Chart

Sonoma Pharmaceuticals Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Other Net Income (Loss)

Get a 7-Day Free Trial

0.24

0.56

Sonoma Pharmaceuticals Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Other Net Income (Loss)	Get a 7-Day Free Trial															-	-	-	-	-

Sonoma Pharmaceuticals Other Net Income (Loss) Calculation

Different companies can and do choose to report each of income statement items separately. Yet, there are a variety of items which are simply too numerous to list. Therefore GuruFocus uses a standardized financial statement format for all companies. Other Net Income (Loss) may include but is not limited to items such as net income (loss) from discontinuing operations, extraordinary, earnings from equity interest net of tax, etc. After-tax income and Other Net Income (Loss) together constitute Net Income Including Noncontrolling Interests.

Other Net Income (Loss) for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.00 Mil.

Sonoma Pharmaceuticals Other Net Income (Loss) Related Terms

Thank you for viewing the detailed overview of Sonoma Pharmaceuticals's Other Net Income (Loss) provided by GuruFocus.com. Please click on the following links to see related term pages.

Sonoma Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sonoma Pharmaceuticals Inc (STU:O8Z) » Definitions » Other Net Income (Loss)

Comparable Companies

Traded in Other Exchanges

SNOA:USA

Address

5445 Conestoga Court, Suite 150, Boulder, CO, USA, 80301

Website

https://www.sonomapharma.com

Sonoma Pharmaceuticals Inc is a specialty pharmaceutical company operating in the United States. It is engaged in identifying, developing, and commercializing differentiated therapies for patients living with chronic skin conditions. The company focuses on the development and commercialization of therapeutic solutions in medical dermatology to treat skin conditions, such as acne, atopic dermatitis, and scarring. The key products of the company are Celacyn, Ceramax Skin Barrier Cream, Mondoxyne, Alevicyn, SebuDerm, Microcyn, and Microcyn which are available for various skin treatments such as scars, itchy skin, minor skin irritations, rashes, and others. The company derives revenue from the sale of products in the United States, Latin America, Europe, Asia, and other countries.

Sonoma Pharmaceuticals Headlines

No Headlines